Conversion of Holmium Laser Enucleation of Prostate to Open Prostatectomy.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 14 07 2021
revised: 05 12 2021
accepted: 12 12 2021
pubmed: 31 12 2021
medline: 3 5 2022
entrez: 30 12 2021
Statut: ppublish

Résumé

To determine the incidence and predictive factors for conversion to an open procedure during Holmium Laser Enucleation of Prostate (HoLEP). A retrospective review was performed on files of all patients that underwent HoLEP at our institution between 2013 and 2020. Data collected included demographics, pre-operative estimated prostate size, intraoperative data, pathologic data, and functional baseline. A univariate and multivariate comparison between the pre-operative data of converted and un-converted cases was conducted. Among a total of 807 HoLEP procedure performed during the above period, 20 cases were converted to open procedures (2.4%). Median pre-operative estimated prostate size in cases of conversion was 228ml compared to 95ml for unconverted cases (P <.001). The reasons for conversion were anatomical in 8 cases (40%), bleeding that was difficult to control endoscopically in 4 cases (20%), expected procedure to be too long due to large prostate size in 6 cases (30%), one case of morcellation technical malfunction, and one case with very large bladder stones not suitable for endoscopic treatment. Prostate size was the only factor that was found to be associated with conversion in univariate and multivariate analysis. The risk of conversion of HoLEP to open procedures is size-dependent. The risk for conversion to open prostatectomy/cystotomy must be communicated to patients who choose HoLEP to improve the informed consent process and provide the highest quality of patient care and transparency. Open prostatectomy/cystotomy should be a part of the armamentarium of every HoLEP surgeon operating on large prostates.

Identifiants

pubmed: 34968568
pii: S0090-4295(21)01177-8
doi: 10.1016/j.urology.2021.12.010
pii:
doi:

Substances chimiques

Holmium W1XX32SQN1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100-104

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Asaf Shvero (A)

Department of Urology, Thomas Jefferson University Hospital, Philadelphia, PA; Department of Urology, Sheba Medical Center, Ramat Gan, Israel. Affiliated with Tel Aviv University, Tel Aviv, Israel. Electronic address: dr.asaf.shvero@hotmail.com.

Timothy M Han (TM)

Department of Urology, Thomas Jefferson University Hospital, Philadelphia, PA.

Andrew Salib (A)

Department of Urology, Thomas Jefferson University Hospital, Philadelphia, PA.

Patrick J Shenot (PJ)

Department of Urology, Thomas Jefferson University Hospital, Philadelphia, PA.

Akhil Das (A)

Department of Urology, Thomas Jefferson University Hospital, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH